CA
NZ
UK
AU
IND
US
…
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -265.94M | -193.51M | -80.74M | -71.04M | -6.55M |
| Net income | -265.94M | -193.51M | -80.74M | -63.42M | -10.80M |
| Selling general administrative | 64.38M | 60.65M | 33.94M | 32.22M | 31.88M |
| Selling and marketing expenses | 53.92M | 41.59M | 40.55M | 39.92M | 35.19M |
| Gross profit | 45.25M | 58.10M | 53.16M | 46.95M | 39.12M |
| Reconciled depreciation | 4.32M | 3.79M | 2.52M | 2.11M | 2.42M |
| Ebit | -254.10M | -179.93M | -69.40M | -78.65M | -78.04M |
| Ebitda | -249.78M | -176.14M | -66.42M | -77.86M | -78.00M |
| Depreciation and amortization | 4.32M | 3.79M | 2.98M | 0.80M | 0.03M |
| Non operating income net other | - | - | - | 14.64M | 78.16M |
| Operating income | -270.02M | -171.78M | -82.38M | -78.65M | -78.04M |
| Other operating expenses | 321.97M | 235.50M | 140.82M | 130.15M | 121.56M |
| Interest expense | 11.84M | 13.58M | 11.34M | 7.02M | 6.67M |
| Interest income | 18.36M | 20.28M | 2.95M | 0.80M | 0.03M |
| Net interest income | 6.52M | 6.71M | -6.09M | -6.22M | -6.64M |
| Income tax expense | - | - | 2.82M | -7.62M | 4.25M |
| Total revenue | 51.82M | 63.72M | 58.44M | 51.49M | 43.52M |
| Total operating expenses | 315.39M | 229.88M | 135.54M | 125.61M | 117.15M |
| Cost of revenue | 6.57M | 5.63M | 5.28M | 4.54M | 4.41M |
| Total other income expense net | 4.08M | -21.73M | 1.65M | 7.62M | 71.48M |
| Net income from continuing ops | -265.94M | -193.51M | -67.06M | -71.04M | -6.55M |
| Net income applicable to common shares | - | - | - | -71.04M | -6.55M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 808.06M | 457.94M | 252.06M | 149.29M | 204.89M |
| Other current assets | 10.86M | 13.46M | 7.79M | 4.03M | 4.75M |
| Total liab | 153.75M | 142.59M | 160.93M | 113.91M | 116.89M |
| Total stockholder equity | 654.31M | 315.34M | 91.13M | 35.38M | 88.00M |
| Deferred long term liab | - | - | - | 6.35M | 20.19M |
| Other current liab | 43.84M | 35.12M | 28.67M | 24.10M | 7.12M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -1157.02M | -891.08M | -697.58M | -616.84M | -545.80M |
| Other liab | - | - | - | 19.83M | 33.19M |
| Other assets | - | - | 0.00M | 1.76M | 1.76M |
| Cash | 737.06M | 392.10M | 195.96M | 102.30M | 164.16M |
| Total current liabilities | 50.81M | 41.35M | 34.90M | 31.39M | 26.34M |
| Current deferred revenue | 14.00M | 0.13M | 0.26M | 0.58M | 13.00M |
| Net debt | -657.28M | -316.32M | -112.57M | -38.02M | -105.18M |
| Short term debt | 2.82M | 1.93M | 1.59M | 1.60M | 1.62M |
| Short long term debt total | 79.78M | 75.78M | 83.39M | 64.28M | 58.98M |
| Other stockholder equity | 1811.31M | 1206.41M | 788.70M | 652.21M | 633.79M |
| Property plant equipment | - | - | - | 9.86M | 11.82M |
| Total current assets | 782.13M | 440.99M | 232.24M | 129.63M | 191.30M |
| Net tangible assets | - | - | - | 35.38M | 88.00M |
| Net receivables | 30.65M | 32.39M | 26.18M | 21.32M | 21.14M |
| Long term debt | 71.34M | 68.50M | 74.92M | 54.01M | 51.44M |
| Inventory | 3.56M | 3.04M | 2.31M | 1.97M | 1.25M |
| Accounts payable | 4.15M | 4.18M | 4.39M | 5.12M | 4.59M |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Retained earnings total equity | - | - | - | -616.84M | -545.80M |
| Non currrent assets other | 1.61M | 1.61M | -0.00M | 1.76M | 1.76M |
| Non current assets total | 25.93M | 16.95M | 19.82M | 19.66M | 13.59M |
| Capital lease obligations | 5.63M | 7.28M | 8.46M | 10.28M | 7.55M |
| Long term debt total | - | - | - | 54.01M | 51.44M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -1.29M | -7.78M | -3.71M | -1.19M |
| Change to liabilities | - | - | - | 1.02M | 2.80M |
| Total cashflows from investing activities | -11.88M | -1.29M | -6.09M | -3.71M | -1.19M |
| Net borrowings | 0.00M | 0.00M | 56.35M | - | -0.45M |
| Total cash from financing activities | 561.72M | 332.11M | 169.83M | 1.45M | 2.85M |
| Change to operating activities | - | - | - | 1.92M | 3.23M |
| Net income | -265.94M | -193.51M | -80.74M | -71.04M | -6.55M |
| Change in cash | 344.96M | 196.15M | 93.51M | -61.86M | -63.89M |
| Begin period cash flow | 393.72M | 197.57M | 104.06M | 165.93M | 229.82M |
| End period cash flow | 738.67M | 393.72M | 197.57M | 104.06M | 165.93M |
| Total cash from operating activities | -204.88M | -134.68M | -70.23M | -59.60M | -65.55M |
| Issuance of capital stock | 541.18M | 316.35M | 9.53M | 0.00M | 0.00M |
| Depreciation | 4.32M | 3.79M | 2.98M | 2.11M | 2.42M |
| Other cashflows from investing activities | 0.13M | - | - | - | - |
| Dividends paid | - | - | 52.57M | - | 0.71M |
| Change to inventory | -0.52M | -0.73M | -0.33M | -0.72M | -0.05M |
| Change to account receivables | 1.74M | -6.21M | -4.85M | -0.19M | -8.88M |
| Sale purchase of stock | 1.59M | 1.02M | 0.85M | 0.94M | 0.98M |
| Other cashflows from financing activities | 561.72M | -300.60M | -4.63M | -3.71M | 7.02M |
| Change to netincome | - | - | - | 3.12M | -58.52M |
| Capital expenditures | 12.01M | 1.29M | 6.09M | 3.71M | 1.19M |
| Change receivables | - | - | - | -0.19M | -8.88M |
| Cash flows other operating | - | - | - | 1.24M | 0.52M |
| Cash and cash equivalents changes | - | - | - | -61.86M | -63.89M |
| Change in working capital | 7.71M | -10.23M | -7.41M | 1.35M | -2.90M |
| Stock based compensation | 43.18M | 33.11M | 17.82M | 16.96M | 14.98M |
| Other non cash items | 5.84M | 32.16M | -2.90M | -8.99M | 4.63M |
| Free cash flow | -216.89M | -135.97M | -76.32M | -63.32M | -66.74M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix Inc |
-0.06 0.79% |
6.92 | - | - | 42.99 | 4.53 | 35.27 | -6.06 |
| NVO Novo Nordisk A/S |
0.29 0.72% |
40.29 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.51 0.99% |
564.39 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
34.06 3.67% |
961.95 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Antony Mattessich | Pres, CEO & Director | 1967 |
| Mr. Donald Notman Jr. | Chief Financial Officer | NA |
| Dr. Peter K. Jarrett Ph.D. | Chief Scientific Officer | 1957 |
| Mr. Philip C. Strassburger | Gen. Counsel | 1960 |
| Mr. William H. Ransone II | VP of Global Sales & Marketing | NA |
| Ms. Tracy Smith | VP of HR | NA |
| Mr. Scott Corning | Sr. VP of Commercial | NA |
| Mr. Christopher G. White | Chief Bus. Officer | 1962 |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer | 1968 |
| Dr. Karen-Leigh Edwards M.B.A., Ph.D. | Sr. VP of Technical Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.80%
Communication Services
+0.61%
Consumer Cyclical
+1.47%
Consumer Defensive
+0.78%
Energy
-1.20%
Financial Services
+0.87%
Financials
+0.88%
Healthcare
-0.33%
Industrials
+0.85%
Real Estate
+0.50%
Technology
+0.39%
Utilities
+0.03%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...